Primacef

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primacef

What is Primacef?

Primacef is a pharmaceutical formulation containing cefuroxime axetil, which is a second-generation cephalosporin antibiotic. It is designed to treat various types of bacterial infections by interfering with the way bacteria build their protective cell walls. By inhibiting this process, the medication leads to the eventual rupture and death of the bacterial cells.

Therapeutic Class and Mechanism

As a member of the cephalosporin family, Primacef is classified as a beta-lactam antibiotic. It is specifically recognized for its broad-spectrum activity, meaning it is effective against a wide range of both Gram-positive and Gram-negative bacteria. This versatility allows it to be used for infections located in different parts of the body.

Common Applications

Primacef is typically utilized for the management of acute and chronic infections where susceptible bacteria are present. Common areas of application include:

  • Respiratory Tract Infections: Such as those affecting the throat, tonsils, sinuses, and bronchial tubes.
  • Urinary Tract Infections: Targeting bacteria that cause infections in the bladder or kidneys.
  • Skin and Soft Tissue Infections: Addressing bacterial growth in skin layers and underlying tissues.
  • Ear Infections: Particularly acute otitis media in pediatric and adult patients.

Because Primacef is an antibiotic, it is only effective against bacterial pathogens. It does not have any therapeutic effect on viral infections, such as the common cold or the flu.

Regulatory References

  1. MedlinePlus: Cefepime Injection

What side effects are possible with Primacef?

Possible Side Effects and Safety Information

Frequency-Classified Adverse Reactions

The officially documented adverse reactions for Cefepime (Primacef) are categorized by frequency, based on clinical data. Common reactions (occurring in 1% to 10% of patients) typically involve a positive Coombs test, diarrhea, rash, and reactions at the injection site such as phlebitis. Less common effects include nausea, vomiting, and temporary changes in blood chemistry, such as elevated liver enzymes (ALT/AST) and increases in blood urea nitrogen (BUN) or creatinine.


Serious Adverse Reactions and Safety Principles

The regulatory safety profile highlights the risk of serious adverse reactions primarily affecting the Nervous System and Immune System. Serious neurological events, including encephalopathy (altered consciousness, confusion), seizures, and myoclonus, are documented. These are often linked to high concentrations of Cefepime in the blood.

Mandatory Safety Principle for Renal Function: The most critical safety principle stated in official labeling is the mandatory dosage adjustment for patients with impaired renal function. Failure to adjust the dose in these patients significantly increases the risk of serious neurotoxicity. Furthermore, Cefepime is contraindicated in patients with a documented history of immediate-type hypersensitivity to Cefepime, any other cephalosporin, or other beta-lactam antibacterial agents, due to the risk of severe allergic reactions like anaphylaxis.

Overdose and Emergency Response

Overdose and When to Seek Help for Primacef (Cefepime)

The official regulatory profile for Cefepime defines the primary concern in cases of overexposure as severe neurotoxicity.

Overdose Manifestations Regulator-Mandated Actions
Central Nervous System (CNS) Disturbances: Symptoms may include encephalopathy, seizures (including nonconvulsive status epilepticus), myoclonus, and profound changes in awareness, such as confusion, altered mental status, decreased responsiveness, and coma. Individuals who observe these neurological symptoms must seek immediate medical attention. The drug must be discontinued right away if neurotoxicity is suspected.
High-Risk Population Note: Overexposure risk is heightened in patients with renal impairment (reduced kidney function) and in geriatric patients due to the potential for drug accumulation. Hemodialysis is documented in official labeling as a procedural measure effective for removing Cefepime from the systemic circulation in severe cases. No specific antidote is known.

Overdose with Cefepime has been associated in official documentation with outcomes classified as life-threatening or fatal when neurological symptoms are not addressed, particularly in at-risk populations. The potential for such serious outcomes necessitates prompt, official emergency response measures as defined by regulatory authorities.

Therapeutic Uses of Primacef

What Primacef Treats: Main Uses and Benefits

Primacef (Cefepime) is commonly used across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort caused by bacterial activity. This medication may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns.

It is relevant for easing the symptomatic distress associated with bloodstream infections (bacteremia), severe respiratory conditions characterized by periods of heightened symptoms (pneumonia), and complicated urinary tract infections and deep skin and soft tissue infections. It is commonly used for conditions associated with acute or disruptive episodes, such as febrile neutropenia (fever in immunocompromised patients).

The treatment supports the patient during difficult episodes by easing distress related to symptoms related to systemic imbalance, such as persistent, high fever and severe chills, and contributes to easing the overall symptom load linked to organ-specific functional stress.


Quick Fact: Therapeutic Focus
Relief Focus: Helps address symptom clusters that may become intense or disruptive.
Use Context: Applied in clinical settings that involve acute or unstable symptom patterns.
Benefit: Provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview on Cefepime Injection

Eligibility and Restrictions for Use

Primacef (which may contain the active ingredient cefazolin, or another cephalosporin antibiotic like cefuroxime or cefixime) is generally prescribed for treating various bacterial infections. Its use is determined by a healthcare professional after assessing the patient’s condition and medical history.

Primacef should not be used by individuals with a documented history of immediate or severe hypersensitivity (allergic reactions) to cephalosporin antibiotics. Due to the potential for cross-reactivity, it is also typically contraindicated in patients who have experienced a severe allergic reaction to penicillin or other beta-lactam antibiotics.

Precautions for Use

Certain patient populations may require careful monitoring, dose adjustments, or specialized medical consultation before using Primacef, including:

Condition Precaution
Allergy to Penicillin Use with caution due to cross-sensitivity risk.
Kidney Impairment Dose adjustment may be necessary.
Gastrointestinal Disease Use with caution, especially a history of colitis.
Pregnancy/Breastfeeding Consult a doctor; benefits must outweigh potential risks.

It is essential to inform a healthcare provider of all existing medical conditions, a full list of current medications, and any history of drug allergies to ensure safe and effective treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Primacef (Cefepime) has officially documented interactions primarily concerning additive toxicity risks, pharmacokinetic sensitivity, and diagnostic interference, as described in regulatory documentation.


Pharmacodynamic and Toxicity Interactions

Interacting Agent Official Regulatory Outcome
Aminoglycoside Antibiotics Increased potential risk of nephrotoxicity and ototoxicity with co-administration.
Potent Diuretics (e.g., Furosemide) Co-administration has been reported to result in nephrotoxicity (a documented class effect).
Oral Anticoagulants Association with reduced prothrombin activity and prolonged prothrombin time (PT).

Pharmacokinetic and Procedural Constraints

Pharmacokinetic Basis: Cefepime elimination is highly dependent on renal excretion. This reliance means that impaired renal function causes reduced clearance and significantly increased plasma concentrations.

Procedural Rules: The co-administration of Aminoglycoside Antibiotics requires separate injection sites or separate administration times to mitigate the documented risk of chemical inactivation.

Population Note: Geriatric patients with renal insufficiency are specifically noted as being at increased risk for serious neurologic adverse reactions due to this reduced clearance.


Diagnostic and Efficacy Interference

  • Administration may cause a false-positive reaction for glucose in the urine when using non-enzymatic test methods.
  • The drug may also cause a positive direct Coombs' test.
  • Co-administration with Intravesical BCG or certain Vaccines may result in reduced therapeutic efficacy of those immunological agents.

Mechanism of Action

The action of Primacef (Cefepime) is strictly focused on the molecular machinery of susceptible bacteria, executing a rapid, bactericidal effect.


Covalent Inhibition of Bacterial Cell Wall Synthesis

The primary mechanism involves the drug acting as an irreversible inhibitor of essential bacterial enzymes called Penicillin-Binding Proteins (PBPs), specifically the transpeptidases. Cefepime binds covalently to the PBPs, immediately halting the cross-linking of peptidoglycan strands, which is the final, critical step in building the structural integrity of the bacterial cell wall. This inhibition, coupled with the activation of the bacteria’s own autolytic enzymes, leads to cell rupture (lysis) and the subsequent biological destruction of the bacterial organism.


️ Limitations Imposed by Bacterial Defense Systems

The effectiveness of this bactericidal mechanism can be constrained by specific bacterial defenses. The most common limitation involves the production of hydrolytic enzymes, such as Extended-Spectrum beta-Lactamases (ESBLs), which destroy the Cefepime molecule before it can reach and inhibit the target PBPs. Additionally, low affinity of Cefepime for certain PBPs or the upregulation of bacterial efflux pumps can reduce the concentration of the drug available to execute its killing mechanism.


Off-Target Effect on CNS Inhibitory Signaling

Under conditions of drug accumulation, particularly in the presence of impaired kidney function, Cefepime can engage an off-target mechanism by weakly antagonizing gamma-Aminobutyric Acid (GABA) Type A receptors in the central nervous system (CNS). This action reduces the natural inhibitory tone mediated by GABA, leading to a reduction of inhibitory signaling and subsequent increase in neuronal activity.

Dosage and Administration Information

Official Administration Guidelines

Primacef (Cefepime) is an antibiotic supplied as a sterile, dry powder for solution for injection and must be administered under professional supervision. The preparation and dosing follow established clinical protocols for this medication.

Category Official Guideline
Route Primarily Intravenous (IV) infusion. Intramuscular (IM) injection is permitted for select mild-to-moderate infections (e.g., uncomplicated UTIs).
Dosing Range Adult doses range from 500 mg to 2 g per dose. The maximal recommended adult frequency is 2 g every 8 hours (Q8h).
Frequency Dosing is typically Every 8 hours (Q8h) for severe conditions (e.g., febrile neutropenia) or Every 12 hours (Q12h) for moderate infections.
Duration The treatment course is usually fixed, ranging from 7 to 10 days, or 7 days for empiric treatment of febrile neutropenia.
Preparation The dry powder must be reconstituted with an approved sterile diluent, then typically diluted further, and inspected for particulate matter before use.

Procedural and Population-Specific Instructions

Administration involves a controlled process. The IV dose must be infused slowly, over approximately 30 minutes. No specific timing relative to meals is required. For pediatric patients (2 months to 16 years), the usual recommended dose is 50 mg/kg per dose, given Q8h or Q12h, not exceeding the adult maximum.

A critical requirement for use in all populations is mandatory dose adjustment in the presence of renal impairment (Creatinine Clearance leq 60 mL/min). The dose must be reduced and/or the interval extended. For patients undergoing hemodialysis, the drug is typically administered after the dialysis session to compensate for drug removal.

Recent Clinical Evidence

Research evidence / Overview of studies for Primacef (Cefepime)

Evidence Structure for Acute Systemic Conditions (Febrile Neutropenia)

Research was conducted exploring Primacef in the setting of febrile neutropenia, a condition associated with acute or disruptive episodes of fever in patients with weakened immune systems. The research was evaluated in numerous Randomized Controlled Trials (RCTs) that compared Primacef monotherapy against other single or combination antibiotic regimens. These studies monitored outcomes related to systemic or functional imbalance, such as the time required for fever to resolve and all-cause mortality over a defined time interval.

Evidence Structure for Severe Respiratory and Systemic Organ Infections

Primacef was the subject of research exploring severe localized infections, including pneumonia and complicated urinary tract infections (UTI). These trials generally monitored two main outcome axes: clinical success (resolution of outcomes related to physical discomfort) and microbiological eradication (clearance of the designated pathogen). Research in this context reported measurements of the composite success rate when compared to active control agents.

Evidence Structure for Skin and Soft Tissue Infections

Studies explored Primacef in research relevant to trials assessing short-term or episodic symptom patterns in uncomplicated skin and soft tissue infections. The findings help contextualize changes measured during the study period related to the evolution of the clinical outcome.

Long-Term Evidence and Follow-up Durations

Long-term effects are not fully established for every indication. While follow-up for major outcomes often extends to 30 days, data on relapse rates or the durability of clinical outcomes over many months are limited.

Evidence in Specific Patient Groups

Primacef was evaluated in studies focusing on special populations, including pediatric patients (children). Research findings described patterns related to the drug's processing in the body (pharmacokinetics) that were observed in subgroups based on renal function. The results apply only to the populations studied.

What the Research Indicates Is Still Uncertain

One of the primary research gaps identified is the historical inconsistency in comparative findings from meta-analyses regarding certain outcomes in the febrile neutropenia setting. This variability means certainty remains low in the comparative evidence for this specific outcome. Additionally, data for certain critically ill or highly specific severe subgroups remain insufficient, and data are still emerging in these areas.

Key Studies & References

  1. Efficacy and safety of cefepime: a systematic review and meta-analysis (addressing mortality controversy)

Frequently Asked Questions (FAQ)

Common questions about Primacef (FAQ)


Q: Is it common to feel tired or fatigued while taking Primacef?

Official reports on side effects do not typically list fatigue or tiredness as a common reaction (occurring in 1% to 10% of patients). However, some patients have reported general feelings of weakness. The drug is associated with a risk of serious neurological events that can include confusion or altered consciousness.


Q: Can Primacef be taken with common pain relievers like ibuprofen or acetaminophen?

Official screening systems based on regulatory data indicate no known drug interactions between Primacef (cefepime) and acetaminophen. Information regarding interactions with non-steroidal anti-inflammatory drugs like ibuprofen is less specific in the core drug label. Official guidance emphasizes that a healthcare provider should review a person’s complete medication list.


Q: Does Primacef interact with hormonal birth control pills?

Cefepime is a broad-spectrum antibiotic and is generally not listed in official documents as a drug that significantly reduces the efficacy of combined hormonal birth control. However, if a person experiences common side effects like diarrhea or vomiting, this could potentially affect the absorption of oral contraceptives. Specific concerns regarding birth control should be addressed with a prescribing healthcare professional.


Q: What if I have liver disease; is Primacef still appropriate for me?

Primacef is mainly cleared by the kidneys, but the risk of serious neurological events is heightened in patients who have both kidney impairment and severe liver disease (cirrhosis) due to potential drug accumulation. The most critical safety principle in this context, according to official labeling, is the mandatory dose adjustment required for kidney impairment.


Q: Does taking Primacef contribute to antibiotic resistance?

Yes, regulatory documents include a warning that Primacef should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria. Misuse, such as taking it for a viral infection or not completing the full course, increases the risk of contributing to the development of drug-resistant bacteria.


Q: Can Primacef cause a yeast infection, and if so, why?

Cefepime is designed to eliminate susceptible bacteria. In rare cases, this broad action can disrupt the body's natural balance of organisms, potentially leading to an overgrowth of fungi (yeast). In rare cases, this may lead to symptoms reported as itching or white patches in the mouth or throat.


Q: How long after finishing the course of Primacef should I watch for delayed side effects?

Official warnings specifically address the risk of severe diarrhea related to Clostridioides difficile infection (CDAD). This condition may occur not only during treatment but also up to two months or more after the antibiotic has been discontinued. The risk of severe diarrhea related to this condition is noted to persist for an extended period.


Q: Are there any known interactions between Primacef and herbal supplements or vitamins?

The official drug label primarily focuses on interactions with other prescription medications. Information on specific interactions with most herbal supplements and vitamins is generally not documented in the core regulatory labeling. Sharing a complete list of all products, including supplements, with a healthcare provider is a critical safety measure.


Q: What are the risks of taking Primacef when it is not needed for a bacterial infection?

Official labeling explicitly warns that taking Primacef for non-bacterial conditions, such as the common cold or flu (viral infections), provides no therapeutic benefit. This unnecessary use increases the risk of contributing to the development of drug-resistant bacteria.


Q: Does Primacef have a generic version available?

Yes. Primacef is a brand name for the active ingredient Cefepime. The FDA has authorized multiple manufacturers to produce and market Cefepime injection, powder, for solution, which are the generic forms. These generic versions contain the same active ingredient and meet the same regulatory standards as the brand-name product.


Q: Why do I need to take all of the Primacef prescription even if I feel better quickly?

Official patient counseling information emphasizes the importance of using the medication for the full prescribed duration, even if symptoms appear to resolve quickly. Stopping the treatment early can increase the risk of the infection recurring or contributing to the development of medication-resistant bacteria.


Q: Is it normal to feel a metallic taste or unusual sensation after taking Primacef?

A metallic taste or an altered sensation of taste (dysgeusia) is not listed as one of the common or less common side effects in the official regulatory documentation for Primacef. Any unusual sensations experienced should be documented and reviewed by a healthcare professional.


Q: Can the side effects of Primacef be managed by taking it with food?

Primacef is administered by injection, not as an oral pill. Because of the route of administration, the official administration guidelines state that no specific timing relative to meals is required. The drug label does not indicate that administering the injection with food would mitigate any of the known side effects.


Q: What if I am taking an antacid; could this affect how Primacef works?

Cefepime is administered via injection directly into the body's circulation. Official interaction screening systems, which rely on regulatory data, generally show no known direct interaction between the injected Primacef and oral antacid products. Official guidance emphasizes caution when using multiple medications concurrently.


Q: What are the benefits of using Primacef compared to the possible risks?

The drug is officially indicated for the treatment of serious bacterial infections, which represents the clinical benefit. Regulatory labeling requires all patients to be informed of the risks, which include the potential for serious neurological reactions and severe allergic reactions, which necessitate careful use under medical supervision.


Q: Does Primacef affect my ability to drive or operate machinery?

Official warnings note the risk of serious neurological side effects, including encephalopathy (altered consciousness), confusion, and seizures. If any of these reactions occur, they will impair the ability to drive or operate machinery. Patients should be aware of the risk of neurotoxicity before attempting activities like driving or operating machinery.


Q: What types of infections is Primacef not effective against?

Cefepime is an antibacterial agent effective only against susceptible bacteria. Official guidance confirms that it is not effective against infections caused by viruses, such as the common cold, flu, or fungi, and should not be used for these purposes.


Q: Is there any evidence about using Primacef for recurring infections?

Official research reports mention that data on long-term patient outcomes, such as relapse rates or the durability of clinical success over many months, are limited. Official research reports indicate that long-term evidence on the durability of clinical success, relevant to recurring infections, is limited.


Q: What are the signs of a non-severe skin reaction to Primacef?

A rash is listed as a common skin-related side effect, occurring in 1% to 10% of patients. Localized reactions, such as inflammation at the injection site, are also common. Patients should be aware that rare, severe reactions (e.g., anaphylaxis) require immediate attention and differ significantly from a common rash.


Q: Is it true that Primacef can cause problems with the gallbladder or liver in rare cases?

Official adverse reaction lists show that Primacef can cause temporary, less common changes in laboratory tests, such as elevated liver enzymes (ALT/AST). While a class of antibiotics to which Primacef belongs has sometimes been associated with liver or gallbladder issues, the primary documented severe safety concern for Cefepime is neurotoxicity.


Q: What research has been done on Primacef's safety in older adults?

The drug label explicitly notes that geriatric patients with impaired kidney function are at increased risk for serious neurologic adverse reactions due to slower drug clearance. This specific warning highlights that the safety profile in older adults requires careful monitoring, particularly when kidney function is reduced.


Q: Does Primacef have any interactions with drugs used for heart conditions or blood thinning?

The official interaction list includes warnings about oral anticoagulants (blood thinners), as co-administration can affect blood clotting time. While the label does not detail all heart condition medications, the combination with potent diuretics (often used for heart failure) is also associated with an increased risk of kidney toxicity.

How should Primacef be stored and disposed of?

How to Store and Dispose of Primacef (Cefepime)

The storage requirements for Primacef (Cefepime for Injection) depend on its form, whether it is the original dry powder or the prepared solution.


Storage Conditions

Product Form Temperature Range Stability/Restrictions
Dry Powder Controlled Room Temp (20 C to 25 C) Must be Protected from Light and kept in the original, tightly closed container.
Prepared Solution Refrigerated (2 C to 8 C) Stable for up to 7 days when refrigerated; stable for 24 hours at room temperature. Do not freeze premixed solutions.

Handling and Disposal

The medicine must be kept out of the reach of children at all times. The solution must be visually inspected for any particulate matter or discoloration before it is administered. Any unused portions of the prepared solution must be discarded. Unused or expired Primacef must not be placed in household trash or poured into wastewater, and should be disposed of as directed by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Primacef found in:

A-Z Index: